Pierluigi Viale
A5045135007- Antibiotics Pharmacokinetics and Efficacy
- Antibiotic Resistance in Bacteria
- Antibiotic Use and Resistance
- Pneumonia and Respiratory Infections
- Bacterial Identification and Susceptibility Testing
- Antifungal resistance and susceptibility
- Antimicrobial Resistance in Staphylococcus
- HIV/AIDS drug development and treatment
- COVID-19 Clinical Research Studies
- HIV-related health complications and treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Nosocomial Infections in ICU
- Orthopedic Infections and Treatments
- HIV Research and Treatment
- Infective Endocarditis Diagnosis and Management
- Liver Disease and Transplantation
- Hepatitis C virus research
- Sepsis Diagnosis and Treatment
- Fungal Infections and Studies
- Liver Disease Diagnosis and Treatment
- SARS-CoV-2 and COVID-19 Research
- HIV/AIDS Research and Interventions
- Long-Term Effects of COVID-19
- Urinary Tract Infections Management
- Streptococcal Infections and Treatments
University of Bologna
2016-2025
Azienda USL di Bologna
2021-2025
Policlinico S.Orsola-Malpighi
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2021-2024
Zambon (Italy)
2024
Azienda Ospedaliero-Universitaria di Modena
2023
University of Modena and Reggio Emilia
2023
Istituto delle Scienze Neurologiche di Bologna
2022
Ospedale D. Cotugno
2022
Centro Cardiologico Monzino
2020
The spread of Klebsiella pneumoniae (Kp) strains that produce K. carbapenemases (KPCs) has become a significant problem, and treatment infections caused by these pathogens is major challenge for clinicians.In this multicenter retrospective cohort study, conducted in 3 large Italian teaching hospitals, we examined 125 patients with bloodstream (BSIs) KPC-producing Kp isolates (KPC-Kp) diagnosed between 1 January 2010 30 June 2011. outcome measured was death within days the first positive...
Infections caused by Klebsiella pneumoniae (Kp) carbapenemase (KPC)-producing strains of Kp have become a significant threat in recent years. To assess their outcomes and identify risk factors for 14 day mortality, we conducted 4 year (2010-13) retrospective cohort study five large Italian teaching hospitals.The included 661 adults with bloodstream infections (BSIs; n = 447) or non-bacteraemic (lower respiratory tract, intra-abdominal structure, urinary tract other sites) KPC-Kp isolate. All...
Abstract Background We evaluated the incidence of invasive pulmonary aspergillosis among intubated patients with critical COVID-19 and different case definitions aspergillosis. Methods Prospective, multicenter study in adult microbiologically confirmed receiving mechanical ventilation. All included participants underwent a screening protocol for bronchoalveolar lavage galactomannan cultures performed on admission at 7 days clinical deterioration. Cases were classified as...
Several factors have been proposed to explain the high death rate of coronavirus disease 2019 (COVID-19) outbreak, including hypertension and hypertension-related treatment with Renin Angiotensin System inhibitors. Also, age multimorbidity might be confounders. No sufficient data are available demonstrate their independent role. We designed a cross-sectional, observational, multicenter, nationwide survey in Italy verify whether renin-angiotensin system inhibitors related COVID-19 severe...
Ceftazidime-avibactam (CAZ-AVI) has been approved in Europe for the treatment of complicated intra-abdominal and urinary tract infections, as well hospital-acquired pneumonia, gram-negative infections with limited options. CAZ-AVI displays vitro activity against Klebsiella pneumoniae carbapenemase (KPC) enzyme producers, but clinical trial data on its efficacy this setting are lacking.We retrospectively reviewed 138 cases caused by KPC-producing K. (KPC-Kp) adults who received...
Despite advances in diagnosis, surgery, and antimicrobial therapy, mortality rates associated with complicated intra-abdominal infections remain exceedingly high.The 2013 update of the World Society Emergency Surgery (WSES) guidelines for management contains evidence-based recommendations patients infections.
ABSTRACT Ceftazidime-avibactam (CAZ-AVI) is a recently approved β-lactam–β-lactamase inhibitor combination with the potential to treat serious infections caused by carbapenem-resistant organisms. Few patients such were included in CAZ-AVI clinical trials, and experience lacking. We present case series of Enterobacteriaceae (CRE) or Pseudomonas aeruginosa (CRPa) who treated salvage therapy on compassionate-use basis. Physicians had prescribed completed report form. used descriptive statistics...
Prolonged treatment with linezolid may cause toxicity. The purpose of this study was to define pharmacodynamic thresholds for improving safety outcomes linezolid.We performed a retrospective patients who had trough (C(min)) and peak (C(max)) plasma levels measured during prolonged treatment. Dosage adjustments were when C(min) ≥10 mg/L and/or AUC₂₄ ≥400 · h. Patients divided into two subgroups according the absence or presence co-treatment rifampicin (the group + group, respectively). Data...
Abstract Background A growing body of observational evidence supports the value ceftazidime-avibactam (CAZ-AVI) in managing infections caused by carbapenem-resistant Enterobacteriaceae. Methods We retrospectively analyzed data on use and outcomes CAZ-AVI therapy for Klebsiella pneumoniae carbapenemase–producing K. (KPC-Kp) strains. Multivariate regression analysis was used to identify variables independently associated with 30-day mortality. Results were adjusted propensity score receipt...
The primary objective of this multicenter, observational, retrospective study was to assess the incidence rate ventilator-associated pneumonia (VAP) in coronavirus disease 2019 (COVID-19) patients intensive care units (ICU). secondary predictors 30-day case-fatality VAP. From 15 February May 2020, 586 COVID-19 were admitted participating ICU. Of them, 171 developed VAP (29%) and included study. 18 events per 1000 ventilator days (95% confidence intervals [CI] 16–21). Deep respiratory...
Mosquito-borne West Nile virus (WNV) infection is benign in most individuals but can cause encephalitis <1% of infected individuals. We show that ∼35% patients hospitalized for WNV disease (WNVD) six independent cohorts from the EU and USA carry auto-Abs neutralizing IFN-α and/or -ω. The prevalence these antibodies highest with (∼40%), silent as low general population. odds ratios WNVD relative to those without them population range 19.0 (95% CI 15.0–24.0, P value <10–15) only...
<h2>Abstract</h2><h3>Objectives</h3> To assess the mortality attributable to infections caused by carbapenem-resistant Enterobacterales (CRE) and investigate effect of clinical management on differences in observed outcomes a multinational matched cohort study. <h3>Methods</h3> A prospective matched-cohorts study (NCT02709408) was performed 50 European hospitals from March 2016 November 2018. The main outcome 30-day with an active post-discharge follow-up when applied. CRE included patients...
<h3>Objective.</h3> —To analyze how demographic, clinical, and laboratory characteristics influence the risk of tuberculosis in human immunodeficiency virus (HIV)— infected individuals; to examine incidence associated with change skin test responsiveness HIV-infected, tuberculin-negative, nonanergic individuals. <h3>Design.</h3> —Multicenter cohort study. <h3>Setting.</h3> —Twenty-three infectious disease units public hospitals Italy. <h3>Subjects.</h3> —A consecutive sample 3397...
The objective of the present retrospective observational study carried out in patients receiving a standard dosage linezolid and undergoing routine therapeutic drug monitoring (TDM) was to assess interindividual variability plasma exposure, identify prevalence attainment optimal pharmacodynamics, define if an intensive program TDM may be warranted some categories patients. Linezolid concentrations (trough [C(min)] peak [C(max)] levels) were analyzed by means high-performance liquid...